Medtronic Plc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BTN1Y115
USD
101.99
-0.04 (-0.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medtronic Plc stock-summary
stock-summary
Medtronic Plc
Pharmaceuticals & Biotechnology
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Company Coordinates stock-summary
Company Details
20 On Hatch, Hatch Street Lower , DUBLIN None : 2
stock-summary
Tel: 353 1 43817001 763 5052692
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 244 Schemes (34.06%)

Foreign Institutions

Held by 526 Foreign Institutions (19.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Geoffrey Martha
Executive Chairman of the Board, President, Chief Executive Officer
Mr. Richard Anderson
Independent Director
Mr. Craig Arnold
Independent Director
Mr. Scott Donnelly
Independent Director
Ms. Andrea Goldsmith
Independent Director
Mr. Randall Hogan
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8,578 Million
(Quarterly Results - Jul 2025)
Net Profit:
1,047 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 119,277 Million (Large Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.08%

stock-summary
Debt Equity

0.43

stock-summary
Return on Equity

11.60%

stock-summary
Price to Book

2.49